The quarter reflected steady revenue growth but underscored challenges in profit conversion, as seen in declining operating ...

The bull market of the past year or more has reinvigorated investors' interest across a range of industries, and the ...

A U.K. court has ruled against Abbott in a trademark infringement case the company had brought over the design of a rival ...

Sales: The California-based device maker is pinning its hopes on Stelo, its recently launched device for adults aged 18 and ...

Reports Q4 revenue $1.11B, consensus $1.10B. “In 2024, we implemented our largest US commercial sales force expansion, had two major product ...

is proud to announce that the Dexcom G7 Continuous Glucose Monitoring (CGM) System has now been added to the Alberta Drug Benefit List. In addition, the Alberta government has expanded the ...

Medical device specialist DexCom (NASDAQ: DXCM) has substantially underperformed the market over the trailing-12-month period ...

Dexcom (Nadsaq:DXCM) shares fell after hours today on fourth-quarter results that came in mixed compared to the consensus forecast.

The Stelo has a 15-day wear time before the sensor needs to be replaced, similar to DexCom's flagship G7 CGM, which has a 10-day wear time. While short-term factors such as above-average ...